FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010828189> ?p ?o ?g. }

• W3010828189 endingPage "498" @default.
• W3010828189 startingPage "490" @default.
• W3010828189 abstract "Objectives To assess the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy in psoriatic arthritis (PsA) dactylitis. Methods Multicentre, investigator-initiated, randomised, double-blind, placebo-controlled, parallel-design phase 3b trial in 11 Portuguese rheumatology centres. Patients with PsA along with active dactylitis and naive to MTX and biologic disease-modifying antirheumatic drugs (bDMARDs) were randomly assigned to golimumab or placebo, both in combination with MTX. The primary endpoint was Dactylitis Severity Score (DSS) change from baseline to week 24. Key secondary endpoints included DSS and Leeds Dactylitis Index (LDI) response, and changes from baseline in the LDI and MRI dactylitis score. Analysis was by intention-to-treat for the primary endpoint. Results Twenty-one patients received golimumab plus MTX and 23 MTX monotherapy for 24 weeks. One patient from each arm discontinued. Patient inclusion was halted at 50% planned recruitment due to a favourable interim analysis. Median baseline DSS was 6 in both arms. By week 24, patients treated with golimumab plus MTX exhibited significantly greater improvements in DSS relative to MTX monotherapy (median change of 5 vs 2 points, respectively; p=0.026). In the golimumab plus MTX arm, significantly higher proportions of patients achieved at least 50% or 70% improvement in DSS and 20%, 50% or 70% improvement in LDI in comparison to MTX monotherapy. Conclusions The combination of golimumab and MTX as first-line bDMARD therapy is superior to MTX monotherapy for the treatment of PsA dactylitis. Trial registration number NCT02065713" @default.
• W3010828189 created "2020-03-23" @default.
• W3010828189 creator A5002875386 @default.
• W3010828189 creator A5003059891 @default.
• W3010828189 creator A5005251731 @default.
• W3010828189 creator A5009065342 @default.
• W3010828189 creator A5009396521 @default.
• W3010828189 creator A5011588493 @default.
• W3010828189 creator A5037882868 @default.
• W3010828189 creator A5040637318 @default.
• W3010828189 creator A5043668531 @default.
• W3010828189 creator A5043747371 @default.
• W3010828189 creator A5044555520 @default.
• W3010828189 creator A5046095798 @default.
• W3010828189 creator A5048248640 @default.
• W3010828189 creator A5050475781 @default.
• W3010828189 creator A5050780548 @default.
• W3010828189 creator A5059136228 @default.
• W3010828189 creator A5060085773 @default.
• W3010828189 creator A5062299635 @default.
• W3010828189 creator A5071482630 @default.
• W3010828189 creator A5071897661 @default.
• W3010828189 creator A5072138537 @default.
• W3010828189 creator A5076981602 @default.
• W3010828189 creator A5082419119 @default.
• W3010828189 creator A5088107398 @default.
• W3010828189 date "2020-03-19" @default.
• W3010828189 modified "2023-09-22" @default.
• W3010828189 title "GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis" @default.
• W3010828189 cites W1522722546 @default.
• W3010828189 cites W1830706163 @default.
• W3010828189 cites W1882277951 @default.
• W3010828189 cites W1895420435 @default.
• W3010828189 cites W1964867500 @default.
• W3010828189 cites W2045317929 @default.
• W3010828189 cites W2054242247 @default.
• W3010828189 cites W2072781796 @default.
• W3010828189 cites W2083180635 @default.
• W3010828189 cites W2085122575 @default.
• W3010828189 cites W2119067278 @default.
• W3010828189 cites W2120232065 @default.
• W3010828189 cites W2131573753 @default.
• W3010828189 cites W2131899204 @default.
• W3010828189 cites W2145778588 @default.
• W3010828189 cites W2162090423 @default.
• W3010828189 cites W2163387772 @default.
• W3010828189 cites W2167795826 @default.
• W3010828189 cites W2171240688 @default.
• W3010828189 cites W2186496667 @default.
• W3010828189 cites W2194197257 @default.
• W3010828189 cites W2195521042 @default.
• W3010828189 cites W2223868808 @default.
• W3010828189 cites W2323625260 @default.
• W3010828189 cites W2400773551 @default.
• W3010828189 cites W2546892737 @default.
• W3010828189 cites W2587876372 @default.
• W3010828189 cites W2604344665 @default.
• W3010828189 cites W2624344118 @default.
• W3010828189 cites W2888063800 @default.
• W3010828189 cites W2907256112 @default.
• W3010828189 cites W2912736897 @default.
• W3010828189 cites W4234517985 @default.
• W3010828189 cites W4323238687 @default.
• W3010828189 doi "https://doi.org/10.1136/annrheumdis-2019-216500" @default.
• W3010828189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7147178" @default.
• W3010828189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32193187" @default.
• W3010828189 hasPublicationYear "2020" @default.
• W3010828189 type Work @default.
• W3010828189 sameAs 3010828189 @default.
• W3010828189 citedByCount "33" @default.
• W3010828189 countsByYear W30108281892020 @default.
• W3010828189 countsByYear W30108281892021 @default.
• W3010828189 countsByYear W30108281892022 @default.
• W3010828189 countsByYear W30108281892023 @default.
• W3010828189 crossrefType "journal-article" @default.
• W3010828189 hasAuthorship W3010828189A5002875386 @default.
• W3010828189 hasAuthorship W3010828189A5003059891 @default.
• W3010828189 hasAuthorship W3010828189A5005251731 @default.
• W3010828189 hasAuthorship W3010828189A5009065342 @default.
• W3010828189 hasAuthorship W3010828189A5009396521 @default.
• W3010828189 hasAuthorship W3010828189A5011588493 @default.
• W3010828189 hasAuthorship W3010828189A5037882868 @default.
• W3010828189 hasAuthorship W3010828189A5040637318 @default.
• W3010828189 hasAuthorship W3010828189A5043668531 @default.
• W3010828189 hasAuthorship W3010828189A5043747371 @default.
• W3010828189 hasAuthorship W3010828189A5044555520 @default.
• W3010828189 hasAuthorship W3010828189A5046095798 @default.
• W3010828189 hasAuthorship W3010828189A5048248640 @default.
• W3010828189 hasAuthorship W3010828189A5050475781 @default.
• W3010828189 hasAuthorship W3010828189A5050780548 @default.
• W3010828189 hasAuthorship W3010828189A5059136228 @default.
• W3010828189 hasAuthorship W3010828189A5060085773 @default.
• W3010828189 hasAuthorship W3010828189A5062299635 @default.
• W3010828189 hasAuthorship W3010828189A5071482630 @default.
• W3010828189 hasAuthorship W3010828189A5071897661 @default.
• W3010828189 hasAuthorship W3010828189A5072138537 @default.
• W3010828189 hasAuthorship W3010828189A5076981602 @default.
• W3010828189 hasAuthorship W3010828189A5082419119 @default.

• next